Replies to post #229277 on Anavex Life Sciences Corp (AVXL)

[BIOChecker4]

Results of a Phase 2a trial are not proof of efficacy, and are certainly not the basis for any regulatory approvals. Much larger, better designed studies will be needed. I wish I had a dollar for every drug that looked great in Phase 2 trials only to flop in Phase 3.

[drv17]

JWC3 - Would you please show your calculations that produces an estimated share price of between $2600 to $13,400. My calculations result in considerably lessor numbers. T/Y

[raja48185]

A2-73 has proven efficacious as a therapy modifying Alzheimer’s.

This therapy will be worth “$13B to $67B in revenue per month.”

So the stock price will be between $2600 and $13400!

To cover the 6.5M short interest at the least sp estimate will require $169B!!!

Appreciate the enthusiasm. However, there is math and there is reality.

To assume that 6.5M short will be covered at $2600 pps is one instance when math goes a bit too far ahead of reality.

Also, my guess is that revenue you are referring to is per year and not per month - a genuine typo ?

Note that I am not going to complain about your numbers for the pps.

Disclosure :Long AVXL since early 2015